Changing Paradigm of Hemophilia Management: Extended Half-Life Factor Concentrates and Gene Therapy

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Seminars in Thrombosis and Hemostasis

• Publication date

  2016-01-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1055/s-0035-1568877PMID 26771678
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates

  2015cited by this paper
• Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients

  2015cited by this paper
• Long‐acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B‐LONG study

  2015cited by this paper
• New approaches to gene and cell therapy for hemophilia

  2015cited by this paper
• Switching from current factor VIII (FVIII) to longer acting FVIII concentrates – what is the real potential benefit?

  2015cited by this paper
• An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia

  2015cited by this paper
• Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A

  2015cited by this paper
• Haemophilia gene therapy: Progress and challenges.

  2015cited by this paper
• Role of enhanced half‐life factor VIII and IX in the treatment of haemophilia

  2015cited by this paper
• The current status of prophylactic replacement therapy in children and adults with haemophilia

  2015cited by this paper
• Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A.

  2015cited by this paper
• Physicochemical characterisation of rVIII-SingleChain, a novel recombinant single-chain factor VIII.

  2015cited by this paper
• Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A

  2014cited by this paper
• The prevalence of neutralizing antibodies against adeno‐associated virus capsids is reduced in young Japanese individuals

  2014cited by this paper
• Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.

  2014cited by this paper
• Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation.

  2014cited by this paper
• Lasting power of new clotting proteins.

  2014cited by this paper
• Changing paradigm of prophylaxis with longer acting factor concentrates

  2014cited by this paper
• Recombinant factor VIII Fc fusion protein: extended‐interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels

  2014cited by this paper
• Costs and utilization of hemophilia A and B patients with and without inhibitors

  2014cited by this paper
• Long-term safety and efficacy of factor IX gene therapy in hemophilia B.

  2014cited by this paper
• Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial.

  2014cited by this paper
• The History of Hemophilia

  2014cited by this paper
• Safety, Efficacy and Pharmacokinetics of Nonacog Beta Pegol (N9-GP) in Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Pediatric Hemophilia B Patients

  2014cited by this paper
• Pharmacokinetic Results of Two Phase III Clinical Studies of Coagulation Factor IX (Recombinant) Albumin Fusion Protein (rIX-FP) in Previously Treated Patients with Hemophilia B (PROLONG-9FP)

  2014cited by this paper
• Bleeding Phenotype with Various Bay 94-9027 Dosing Regimens: Subanalyses from the Protect VIII Study

  2014cited by this paper
• Our Journey to Successful Gene Therapy for Hemophilia B

  2014cited by this paper
• Anti‐factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation

  2014cited by this paper
• Current status of haemophilia gene therapy

  2014cited by this paper
• The history of haemophilia - a short review.

  2014cited by this paper
• Clinical presentation and molecular basis of congenital antithrombin deficiency in children: a cohort study

  2014cited by this paper
• Definitions in hemophilia: communication from the SSC of the ISTH

  2014cited by this paper
• Novel products for haemostasis – current status

  2014cited by this paper
• Enhancing the pharmacokinetic properties of recombinant factor VIII: first‐in‐human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A

  2013cited by this paper
• History of prophylaxis

  2013cited by this paper
• Gene therapy for hemophilia

  2013cited by this paper
• Randomized, controlled, parallel‐group trial of routine prophylaxis vs. on‐demand treatment with sucrose‐formulated recombinant factor VIII in adults with severe hemophilia A (SPINART)

  2013cited by this paper
• Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.

  2013cited by this paper
• Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study

  2013cited by this paper
• Consequences of switching from prophylactic treatment to on‐demand treatment in late teens and early adults with severe haemophilia A: the TEEN/TWEN study

  2013cited by this paper
• Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant.

  2013cited by this paper
• Inherited abnormalities of coagulation: hemophilia, von Willebrand disease, and beyond.

  2013cited by this paper
• Pharmacokinetics Of Recombinant Factor IX Fc Fusion Protein (rFIXFc) In Pediatric Subjects With Hemophilia B: An Interim Analysis Of The Kids B-LONG Study

  2013cited by this paper
• Management of bleeding disorders in children

  2012cited by this paper
• Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.

  2012cited by this paper
• A study of variations in the reported haemophilia B prevalence around the world

  2012cited by this paper
• Modern haemophilia care.

  2012cited by this paper
• Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia.

  2012cited by this paper
• Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.

  2012cited by this paper
• A complex substitute: antibody therapy for hemophilia

  2012cited by this paper
• New treatments in hemophilia: insights for the clinician

  2012cited by this paper
• Treatment patterns, health‐related quality of life and adherence to prophylaxis among haemophilia A patients in the United States

  2012cited by this paper
• Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients.

  2012cited by this paper
• A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model

  2012cited by this paper
• Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model.

  2012cited by this paper
• Current prescription of prophylactic factor infusions and perceived adherence for children and adolescents with haemophilia: a survey of haemophilia healthcare professionals in the United States

  2012cited by this paper
• Hemostatic properties of a TFPI antibody.

  2012cited by this paper
• Magnetic resonance imaging and joint outcomes in boys with severe hemophilia A treated with tailored primary prophylaxis in Canada

  2012cited by this paper
• A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)

  2011cited by this paper
• Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B.

  2011cited by this paper
• BAX 855, a PEGylated rFVIII product with prolonged half-life

  2011cited by this paper
• Venous access in the management of hemophilia.

  2011cited by this paper
• Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.

  2011cited by this paper
• A United Kingdom Haemophilia Centre Doctors’ Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A

  2010cited by this paper
• A study of variations in the reported haemophilia A prevalence around the world

  2010cited by this paper
• Efficacy and safety of secondary prophylactic vs. on‐demand sucrose‐formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13‐month crossover study

  2010cited by this paper
• Haemophilia in Sweden. III. Symptomatology, with special reference to differences between haemophilia A and B.

  2009cited by this paper
• Genetic fusion to albumin improves the pharmacokinetic properties of factor IX

  2009cited by this paper
• Genotype Analysis Identifies the Cause of the “Royal Disease”

  2009cited by this paper
• Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.

  2007cited by this paper
• Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study

  2006cited by this paper
• Gene therapy for hemophilia A.

  2006cited by this paper
• A passionate kiss, then run: exocytosis and recycling of IgG by FcRn.

  2005cited by this paper
• Can long‐term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands

  2005cited by this paper
• Management of bleeding disorders in children.

  2005cited by this paper
• 1002. Immune Responses to AAV and to Factor IX in a Phase I Study of AAV-Mediated, Liver-Directed Gene Transfer for Hemophilia B

  2004cited by this paper
• A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres

  2003cited by this paper
• AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.

  2003cited by this paper
• A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency.

  2003cited by this paper
• Report of a second serious adverse event in a clinical trial of gene therapy for X‐linked severe combined immune deficiency (X‐SCID)

  2003cited by this paper
• Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion.

  2003cited by this paper
• Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy.

  2003cited by this paper
• The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia.

  2002cited by this paper
• Hemophilia and related bleeding disorders: a story of dismay and success.

  2002cited by this paper
• Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy

  2002cited by this paper
• The hemophilias--from royal genes to gene therapy.

  2001cited by this paper
• Barriers to compliance with prophylaxis therapy in haemophilia

  2001cited by this paper
• Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A.

  2001cited by this paper
• Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector

  2000cited by this paper
• Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized

  1999cited by this paper
• THE HISTORY OF HAEMOPHILIA IN THE ROYAL FAMILIES OF EUROPE

  1999cited by this paper
• When should prophylactic treatment in patients with haemophilia A and B start?— The German experience

  1998cited by this paper
• New-variant Creutzfeldt-Jakob disease and treatment of haemophilia.

  1998cited by this paper
• New-variant Creutzfeldt-Jakob disease and treatment of haemophilia. Executive Committee UK Haemophilia Directors' Organisation.

  1998cited by this paper
• A factor IX-deficient mouse model for hemophilia B gene therapy.

  1997cited by this paper
• Implantation of autologous skin fibroblast genetically modified to secrete clotting factor IX partially corrects the hemorrhagic tendencies in two hemophilia B patients.

  1996cited by this paper
• Modern treatment of haemophilia.

  1995cited by this paper
• Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B

  1992cited by this paper
• Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia.

  1989cited by this paper
• Development of factor VIII:C antibodies in dogs with hemophilia A (factor VIII:C deficiency).

  1984cited by this paper

• Nanoparticle-Hydrogel Sustained-Release System for the Delivery of si-NEDD4: A Promising Strategy for the Treatment of Keloids.

  2025cites this paper
• The Evolution of Hemophilia Pharmacological Treatments and Therapeutic Targets at the Turn of the Third Millennium

  2024cites this paper
• 2023 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

  2023cites this paper
• Analysis of nationwide hemophilia care: A cohort study using two Japanese healthcare claims databases

  2022cites this paper
• Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia

  2022cites this paper
• 2020 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards

  2021cites this paper
• Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective

  2021cites this paper
• Terminal half‐life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database

  2021cites this paper
• Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Austria

  2021cites this paper
• 2019 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards

  2020cites this paper
• Prophylaxis for hemophilia A without inhibitors: treatment options and considerations

  2020cites this paper
• 2018 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards

  2019cites this paper
• Merging into the mainstream: the evolution of the role of point-of-care musculoskeletal ultrasound in hemophilia

  2019cites this paper
• 45 years of Seminars in Thrombosis and Hemostasis

  2018cites this paper
• 2018 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

  2018cites this paper
• Towards harmonization of external quality assessment/proficiency testing in hemostasis

  2018cites this paper
• The current and future role of plasma-derived clotting factor concentrate in the treatment of haemophilia A.

  2018cites this paper
• 2017 Eberhard F. Mammen Award Announcements: Part II–Young Investigator Awards

  2018cites this paper
• Postanalytical considerations that may improve the diagnosis or exclusion of haemophilia and von Willebrand disease

  2018cites this paper
• Comparison of F13A1 gene mutations in 73 patients treated with recombinant FXIII‐A2

  2017cites this paper
• 2016 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards

  2017cites this paper
• Management of Hemophilia in Older Patients

  2017cites this paper
• Emerging treatments for hemophilia: patients and their treaters spoilt for choice, but laboratories face a difficult path?

  2017cites this paper
• Laboratory tests used to help diagnose von Willebrand disease: an update.

  2016cites this paper
• Baby hamster kidney cell–derived recombinant factor VIII: a quarter century of learning and clinical experience

  2016influential citation
• Editorial Compilation I

  2016cites this paper
• New therapies for hemophilia.

  2016cites this paper
• 2015 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards

  2015cites this paper